Finasteride-its impact on sexual function and prostate cancer.

Anitha B, Inamadar AC, Regunatha S.

dc.contributor.author	Anitha B, Inamadar AC, Regunatha S.
dc.date.accessioned	2020-01-02T10:12:41Z
dc.date.available	2020-01-02T10:12:41Z
dc.date.issued	2009-07
dc.identifier.uri	http://hdl.handle.net/123456789/1553
dc.description.abstract	Finasteride, a specific and competitive inhibitor of 5α-reductase enzyme Type 2, inhibits the conversion of testosterone to dihydrotestosterone (DHT). In adults, DHT acts as primary androgen in prostate and hair follicles. The only FDA-approved dermatological indication of finasteride is androgenetic alopecia. But, apprehension regarding sexual dysfunction associated with finasteride deters dermatologists from prescribing the drug and patients from taking the drug for androgenetic alopecia.	en_US
dc.language.iso	en	en_US
dc.publisher	BLDE(Deemed to be University)	en_US
dc.subject	Finasteride, prostate cancer, sexual function	en_US
dc.title	Finasteride-its impact on sexual function and prostate cancer.	en_US
dc.type	Article	en_US